Sarepta Therapeutics, Brazilian depositary receipt (BDR)
BRS1RPBDR005, S1RP34

Name: Sarepta Therapeutics (S1RP34) Stock Price Quote
Creator: Cbonds
License: https://creativecommons.org/licenses/by/4.0/

Add a stock to WL

Choose all Reset all

Save Close

Sarepta Therapeutics, сountry — USA

No trading data

Data display in a chart | table

Source of information - PJSC "MOEX". Further disctribution of MOEX information is prohibited without prior consent with PJSC "MOEX".

from

ADD-IN
Cbonds add-in API
bond data api

Authorization required

You need to request access

More than 2,500 records have been found, please specify your request

No data for the selected period

Latest quotes

explore the most comprehensive database

800 000

bonds globally

Over 400

pricing sources

80 000

stocks

9 000

ETF

track your portfolio in the most efficient way

Bond Search

Watchlist

Excel ADD-IN

Get access

— Are you looking for the complete & verified bond data?

— We have everything you need:

full data on over 700 000 bonds, stocks & ETFs; powerful bond screener; over 350 pricing sources among stock exchanges & OTC market; ratings & financial reports; user-friendly interface; available anywhere via Website, Excel Add-in and Mobile app.

Why

You will have detailed descriptive & pricing data for 650K bonds, 76K stocks, 8K ETFs

Get full access to the platform from any device & via Cbonds app

Enhance your portfolio management with Cbonds Excel Add-in

Build yield maps, make chart comparison within a click

Don't wait any longer — start using Cbonds today! Register

Issuer

Profile

Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin. It also develops SRP-4045 and SRP-4053, which are exon skipping clinical product candidates for the treatment of DMD. The company distributes its products through a network of specialty distributors and specialty pharmacies in the United States. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.

Show more Hide

Issuer

Sarepta Therapeutics
Full borrower / issuer name

Sarepta Therapeutics, Inc.
Industry

Pharmaceutical Preparation and Biotechnology

IFRS/US GAAP reports

2024
	I q eng



2023
	I q eng
	II q eng
	III q eng
	IV q eng
2022
	I q eng
	II q eng
	III q eng
	IV q eng
2021
	I q eng
	II q eng
	III q eng
	IV q eng
2020
	I q eng
	II q eng
	III q eng
	IV q eng
2019
	I q eng
	II q eng
	III q eng
	IV q eng
2018
	I q eng
	II q eng
	III q eng
	IV q eng
2017
	I q eng
	II q eng
	III q eng
	IV q eng
2016
	I q eng
	II q eng
	III q eng
	IV q eng
2015
	I q eng
	II q eng
	III q eng
	IV q eng
2014



	IV q eng

Show all Hide

Authorization required

You need to request access

Indicators

News

08/01/2024	Sarepta Therapeutics: Results Of Operations And Financial Condition, Regulation Fd Disclosure, Financial Statements And Exhibits
22/06/2023	Sarepta Therapeutics: Regulation Fd Disclosure, Financial Statements And Exhibits
22/06/2023	Sarepta Therapeutics: Regulation Fd Disclosure, Financial Statements And Exhibits
08/06/2023	Sarepta Therapeutics: Departure Of Directors Or Certain Officers; Election Of Directors; Appointment Of Certain Officers; Compensatory Arrangements Of Certain Officers, Submission Of Matters To A Vote Of Security Holders, Financial Statements And Exhibits
02/03/2023	Sarepta Therapeutics: Entry Into A Material Definitive Agreement, Unregistered Sales Of Equity Securities, Financial Statements And Exhibits

Sarepta Therapeutics, Brazilian depositary receipt (BDR)
BRS1RPBDR005, S1RP34

Stock information